Levels of evidence: Further insight on Gugiu and Gugiu

Evaluation and the Health Professions

Volumn 34, Issue 1, 2011, Pages 124-126

  Berger, Vance W ^a   Knoll, Diana ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; EPIDEMIOLOGY; EVIDENCE BASED MEDICINE; HUMAN; METHODOLOGY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL ANALYSIS;

CAUSALITY; DATA INTERPRETATION, STATISTICAL; EVIDENCE-BASED MEDICINE; GUIDELINES AS TOPIC; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 79551631672     PISSN: 01632787     EISSN: 15523918     Source Type: Journal    
DOI: 10.1177/0163278710391466     Document Type: Article

References (7)

1. Berger, V.W. (2005). Quantifying the magnitude of baseline covariate imbalances resulting from selection bias in randomized clinical trials. Biometrical Journal, 47, 119-127.
2. Berger, V.W. (2009). A fatally flawed trial. Annals of Internal Medicine. First published online, March 16, 2009, http://www.annals.org/content/150/4/255.abstract/reply.
3. Berger, V.W., & Alperson, S.Y. (2009). A general framework for the evaluation of clinical trial quality. Reviews on Recent Clinical Trials, 4, 79-88.
4. Berger, V.W., & Bears, J.D. (2003). When can a clinical trial be called 'randomized'? Vaccine, 21, 468-472.
5. Berger, V.W., Lunneborg, C.E., Ernst, M.D., & Levine, J.G. (2002). Parametric analyses in randomized clinical trials. Journal of Modern Applied Statistical Methods, 1, 74-82.
6. Emons, W. (1997). Credence goods and fraudulent experts. RAND Journal of Economics, 28, 107-119.
7. Gugiu, P.C., & Gugiu, M.R. (2010). A critical appraisal of standard guidelines for grading levels of evidence. Evaluation & the Health Professions, 33, 233-255.